OnKure Therapeutics (OKUR) director receives 22,350 options at $4.14 strike

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. reported that director Edward T. Mathers received a grant of 22,350 stock options on August 7, 2026. The options carry an exercise price of $4.14 per share and are exercisable for Class A Common Stock. All of the shares subject to the option vest on the earlier of June 4, 2027 or the day prior to the company's next annual meeting of stockholders, subject to his continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 derivative securities of this type directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mathers Edward T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	22,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,350 shares (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Stock options granted: 22,350 shares Exercise price: $4.14 per share Expiration date: August 6, 2036 +2 more

5 metrics

Stock options granted 22,350 shares Stock Option (right to buy) granted on August 7, 2026

Exercise price $4.14 per share Conversion or exercise price of the granted options

Expiration date August 6, 2036 Expiration of Stock Option (right to buy)

Vesting date trigger June 4, 2027 100% vests on earlier of June 4, 2027 or day before next annual meeting

Holdings after grant 22,350 derivative securities Total Stock Option holdings following the reported transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to the option will vest on the earlier of June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the day prior to the date of the Issuer's next annual meeting of stockholders"

FAQ

What did OnKure Therapeutics (OKUR) disclose about Edward T. Mathers in this Form 4?

OnKure Therapeutics disclosed that director Edward T. Mathers received a grant of 22,350 stock options on August 7, 2026, with an exercise price of $4.14 per share, vesting based on continued service.

How many options did Edward T. Mathers acquire in the latest OKUR filing?

Edward T. Mathers acquired 22,350 stock options for OnKure Therapeutics Class A Common Stock. These options vest in full on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, subject to continued service.

What is the exercise price of Edward T. Mathers’ options reported for OKUR?

The options granted to Edward T. Mathers have an exercise price of $4.14 per share. They are stock options to purchase OnKure Therapeutics Class A Common Stock and expire on August 6, 2036, if not exercised earlier.

When do the newly granted OKUR options to Edward T. Mathers vest?

All 22,350 options vest on the earlier of June 4, 2027 or the day prior to OnKure Therapeutics' next annual meeting of stockholders, provided Edward T. Mathers continues as a service provider through the applicable vesting date.

What is Edward T. Mathers’ total derivative holdings after this OKUR option grant?

After the reported transaction, Edward T. Mathers directly holds 22,350 derivative securities of this option type. These represent stock options for OnKure Therapeutics Class A Common Stock granted at an exercise price of $4.14 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:44 PM Accepted by SEC EDGAR 08/11/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathers Edward T

(Last) (First) (Middle)

104 5TH AVE

19TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		22,350		(1)	08/06/2036	Class A Common Stock	22,350	$0	22,350	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Zachary Bambach, attorney-in-fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)